Resmed (RMD) Notes Payables (2015 - 2026)

Resmed has reported Notes Payables for 12 years, with the latest figure at $259.9 million in Q1 2026.

• For the quarter ending Q1 2026, Notes Payables rose 2523.95% year-over-year to $259.9 million; the trailing twelve-month figure through Mar 2026 stood at $259.9 million (up 2523.95% YoY), and the FY2025 full-year result was $9.9 million, changed 0.0% from the prior year.
• Notes Payables for Q1 2026 stood at $259.9 million, roughly flat from $259.9 million in the prior quarter.
• The five-year high for Notes Payables was $259.9 million in Q1 2026, with the low at $9.9 million in Q3 2024.
• Historically, Notes Payables has averaged $54.1 million across 5 years, with a median of $9.9 million in 2023.
• Annual changes were most pronounced in 2022 — Notes Payables slipped 17.5% — and 2025, when it jumped 2526.3%.
• Resmed's Notes Payables stood at $9.9 million in 2022, then retreated by 0.02% to $9.9 million in 2023, then climbed by 0.08% to $9.9 million in 2024, then jumped by 2523.72% to $259.9 million in 2025, then climbed by 0.01% to $259.9 million in 2026.
• The last three Notes Payables figures came in at $259.9 million (Q1 2026), $259.9 million (Q4 2025), and $259.9 million (Q3 2025), per Business Quant data.